It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

 


Dosing Cycle▾  |   How to Administer

Convenient dosing and administration

ZIEXTENZO is administered once per cycle as a subcutaneous injection, following the same dosing schedule and route of administration as Neulasta®1,2

ZIEXTENZO 6 mg/0.6 mL prefilled syringe.

Convenient, once-per-cycle dosing is the same as Neulasta®1,2

  ZIEXTENZO
Indication
  • ZIEXTENZO is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia1

ZIEXTENZO is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.1

Dosage forms Injection: 6 mg/0.6 mL prefilled syringe1
Active ingredient Pegfilgrastim-bmez1
Administration

ZIEXTENZO is administered as a single-dose subcutaneous injection once per chemotherapy cycle.1

  • ZIEXTENZO is supplied as a 6 mg/0.6 mL solution in a single-dose prefilled syringe for manual subcutaneous injection (NDC 61314-866-01)1
  • It is available with a BD™ UltraSafe Passive® Needle Guard that provides one-handed passive activation1,3
  • Do not administer ZIEXTENZO between 14 days before and 24 hours after administration of cytotoxic chemotherapy1

In-home administration is another option for your ZIEXTENZO patients

For patients who cannot make their injection appointments, see how ZIEXTENZO can be self-administered or administered by a caregiver.

Self-administering ZIEXTENZO

Administering ZIEXTENZO as a caregiver

BD is a trademark of Becton, Dickinson and Company. UltraSafe Passive is a registered trademark of Safety Syringes, Inc.
Neulasta is a registered trademark of Amgen Inc.

References: 1. ZIEXTENZO Prescribing Information. Sandoz Inc. September 2020. 2. Neulasta Prescribing Information. Amgen Inc. January 2020. 3. BD safety and shielding systems. BD Drug Delivery Systems website. https://drugdeliverysystems.bd.com/products/safety-and-shielding-systems/ultrasafe-passive-needle-guard. Accessed October 13, 2020.